Immutep faces legal scrutiny amid securities claims investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2026
0mins
Source: Globenewswire
Immutep Ltd's stock price surged by 50.35% in pre-market trading, crossing above the 5-day SMA, indicating a significant upward movement despite recent challenges.
The Rosen Law Firm is investigating potential securities claims against Immutep Ltd. due to allegations of misleading business information, which may have led to significant investor losses. This follows the discontinuation of the TACTI-004 Phase III study, which was deemed ineffective, reflecting extreme market pessimism. The firm is preparing a class action to recover investor losses, allowing shareholders to participate without upfront fees, demonstrating a commitment to protecting investor rights.
The ongoing investigation and potential class action may create further volatility for Immutep's stock as investors weigh the implications of these legal challenges against the recent price surge.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.445
Low
12.00
Averages
12.00
High
12.00
Current: 0.445
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, claiming strong progress while knowing the risks of failing to meet primary efficacy and safety endpoints, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Immutep ADR Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency regarding clinical trials.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between March 24, 2025, and March 12, 2026.
- False Statements: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before July 6, 2026, to participate in the lawsuit and seek recovery.
- Legal Proceedings: The class in this case has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their claims.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to seek compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information was disclosed, highlighting significant risks associated with the company's trial outcomes.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this field.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
Immutep Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased Immutep Limited's ADRs between March 24, 2025, and March 12, 2026, potentially exposing the company to legal risks that could impact its stock performance.
- Allegations of Misrepresentation: The lawsuit alleges that defendants made materially false and misleading statements regarding the company's business operations, growth prospects, and financial stability, resulting in Immutep ADRs being traded at artificially inflated prices during the class period, causing significant losses for investors.
- Investor Action Guidance: Affected investors are encouraged to file papers by July 6, 2026, to serve as lead plaintiff in the class action, although those who choose not to participate can still share in any recovery, highlighting the complexities of legal proceedings and investor options.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List,” indicating the firm's strong legal expertise and reputation in handling class actions.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, necessitating an orderly wind-down and patient follow-up, reflecting a major setback in its R&D pipeline that could undermine future market confidence.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, showcasing extreme pessimism in the market regarding the company's outlook.
- Legal Firm Background: Pomerantz LLP, a prominent firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit could lead to substantial damages against Immutep, exacerbating its financial pressures.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed negative information regarding the TACTI-004 trial, claiming strong progress while knowing the risks of failing to meet primary efficacy and safety endpoints, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Immutep ADR Class Action Notice Issued
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, that they must apply to be lead plaintiffs by July 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's transparency regarding clinical trials.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its capability and experience in handling similar cases.
- Investor Selection Advice: Investors are advised to choose law firms with proven success to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
Immutep Faces Class Action Lawsuit for Securities Violations
- Lawsuit Background: The Schall Law Firm reminds investors of a class action lawsuit against Immutep Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, concerning securities purchased between March 24, 2025, and March 12, 2026.
- False Statements: The complaint alleges that Immutep concealed the results of its TACTI-004 trial of eftilagimod alfa, as the company claimed in a Form-K filed with the SEC on January 30, 2026, that the trial was showing “strong operational progress,” despite knowing it would fail to meet primary efficacy endpoints.
- Investor Losses: Following the revelation of the truth about Immutep, investors suffered damages, and the Schall Law Firm encourages affected investors to contact them before July 6, 2026, to participate in the lawsuit and seek recovery.
- Legal Proceedings: The class in this case has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to act will remain absent class members, potentially forfeiting their claims.
See More
Immutep ADRs Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, to apply as lead plaintiffs by July 6, 2026, to seek compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses when the true information was disclosed, highlighting significant risks associated with the company's trial outcomes.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this field.
- Investor Action Recommendation: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
Immutep Shareholder Files Securities Class Action Lawsuit
- Class Action Initiated: Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors who purchased Immutep Limited's ADRs between March 24, 2025, and March 12, 2026, potentially exposing the company to legal risks that could impact its stock performance.
- Allegations of Misrepresentation: The lawsuit alleges that defendants made materially false and misleading statements regarding the company's business operations, growth prospects, and financial stability, resulting in Immutep ADRs being traded at artificially inflated prices during the class period, causing significant losses for investors.
- Investor Action Guidance: Affected investors are encouraged to file papers by July 6, 2026, to serve as lead plaintiff in the class action, although those who choose not to participate can still share in any recovery, highlighting the complexities of legal proceedings and investor options.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List,” indicating the firm's strong legal expertise and reputation in handling class actions.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, indicating significant legal risks that could tarnish the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep disclosed that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III study, necessitating an orderly wind-down and patient follow-up, reflecting a major setback in its R&D pipeline that could undermine future market confidence.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, showcasing extreme pessimism in the market regarding the company's outlook.
- Legal Firm Background: Pomerantz LLP, a prominent firm in securities class litigation with over 85 years of experience, focuses on advocating for victims of securities fraud, and this lawsuit could lead to substantial damages against Immutep, exacerbating its financial pressures.
See More
